Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nichi-Iko and Eisai devise Japan alliance

Executive Summary

Nichi-Iko is set to obtain by 1 April next year all shares in Eisai’s Elmed Eisai value-added generic pharmaceuticals business in Japan, while Nichi-Iko and Elmed Eisai also plan to “integrate their strengths” and co-promote one another’s generic products in the country, as part of a broader, three-part, strategic alliance agreement.

You may also be interested in...

Nichi-Iko Falls Short Of Target

Despite seeing sales through its US Sagent unit hit by supply issues with CMOs, Nichi-Iko says its US profits have increased on the back of newly-launched products. However, this failed to offset the impact of NHI price revisions in Japan, dragging down profits in the first nine months of the year.

Nichi-Iko And Eisai Expand Alliance To China

Nichi-Iko and Eisai have announced plans to build on their Japanese generics collaboration by expanding the partnership into China.

Sandoz Egypt Partners Up To Launch Rituximab Biosimilar

Sandoz’ operation in Egypt has banded together with the Egyptian Cancer Society to introduce the firm’s biosimilar to Roche’s Rituxan/MabThera, three years after Hikma in-licensed a rituximab biosimilar from Celltrion.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts